{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:25:56Z","timestamp":1770740756081,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009142","name":"Cancer Care Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.clon.2016.09.006","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T23:48:56Z","timestamp":1475711336000},"page":"e5-e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Early-stage Hodgkin Lymphoma: A Practice Guideline"],"prefix":"10.1016","volume":"29","author":[{"given":"J.","family":"Herst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Crump","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-9371","authenticated-orcid":false,"given":"F.G.","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-0743","authenticated-orcid":false,"given":"J.","family":"MacEachern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clon.2016.09.006_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2016.09.006_bib2","series-title":"GRADE handbook for grading quality of evidence and strength of recommendations","year":"2013"},{"issue":"23","key":"10.1016\/j.clon.2016.09.006_bib3","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.clon.2016.09.006_bib4","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/JCO.2003.01.044","article-title":"Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133","volume":"21","author":"Ganz","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.clon.2016.09.006_bib5","first-page":"177","article-title":"Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up","volume":"110","author":"Rancea","year":"2013","journal-title":"Dtsch Arztebl Int"},{"issue":"21","key":"10.1016\/j.clon.2016.09.006_bib6","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.clon.2016.09.006_bib7","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2016.09.006_bib8","series-title":"7th International Symposium on Hodgkin Lymphoma, November 2007","first-page":"C010","article-title":"Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage hodgkin\u2019s lymphoma (HL)","author":"Thomas","year":"2007"},{"issue":"12","key":"10.1016\/j.clon.2016.09.006_bib9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.clon.2016.09.006_bib10","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.clon.2016.09.006_bib11","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.clon.2016.09.006_bib12","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.clon.2016.09.006_bib13","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.clon.2016.09.006_bib14","article-title":"Selection of patients for minimal initial chemotherapy (MIC); the impact of Hasenclever score on outcome in patients receiving MIC and involved field radiotherapy for clinical stage IA\/IIA supra-diaphragmatic Hodgkin lymphoma in the UK NCRI LY07 trial","volume":"92","author":"Thistlethwaite","year":"2007","journal-title":"Haematol Abstr Book"},{"issue":"27","key":"10.1016\/j.clon.2016.09.006_bib15","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.clon.2016.09.006_bib16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.clon.2016.09.006_bib17","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1002\/cncr.25295","article-title":"Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial","volume":"116","author":"Arakelyan","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clon.2016.09.006_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5144\/1658-3876.2012.36","article-title":"A\u00a0randomized trial of brief treatment of early-stage Hodgkin lymphoma: is it effective?","volume":"5","author":"Hamed","year":"2012","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"10.1016\/j.clon.2016.09.006_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/annonc\/mdm575","article-title":"ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study","volume":"19","author":"Pavone","year":"2008","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.clon.2016.09.006_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.416.416","article-title":"Randomized phase III trial comparing ABVD plus radiotherapy and the Stanford V regimen In patients with stage I\/II bulky mediastinal Hodgkin lymphoma: a subset analysis of the US Intergroup Trial E2496","volume":"116","author":"Advani","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clon.2016.09.006_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2003-05-1611","article-title":"Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial","volume":"103","author":"Le Maignan","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clon.2016.09.006_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.clon.2016.09.006_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.1603.1603","article-title":"Patterns of failure in patients with stage I\/II bulky mediastinal Hodgkin lymphoma (HL) treated with ABVD plus radiotherapy or the Stanford V regimen in the randomized phase III North American Intergroup Trial: E2496","volume":"118","author":"Advani","year":"2011","journal-title":"Blood"},{"issue":"9976","key":"10.1016\/j.clon.2016.09.006_bib24","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clon.2016.09.006_bib25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial","volume":"30","author":"Von Tresckow","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516303004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516303004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:42:52Z","timestamp":1760542972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655516303004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0936655516303004"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2016.09.006","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Early-stage Hodgkin Lymphoma: A Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2016.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}